恩替卡韦与阿德福韦酯对慢性乙型肝炎的成本-效果分析.PDFVIP

·2322 · Drug Evaluation Research 第41 卷第12 期 2018 年12 月 恩替卡韦与阿德福韦酯对慢性乙型肝炎的成本-效果分析 张亚峰，王 鹏 渭南市中心医院，陕西 渭南 714000 摘 要：目的 分析恩替卡韦与阿德福韦酯对慢性乙型肝炎的成本-效果。方法 将 84 例慢性乙型肝炎患者随机分为恩替卡 韦组40 例和阿德福韦酯组44 例治疗，两组均治疗观察 12个月。运用药物经济学方法分析其成本-效果 （C/E）。结果 治疗3 个月恩替卡韦组丙氨酸氨基转移酶 （ALT ）复常率明显高于阿德福韦酯组，差异有统计学意义 （P ＜0.05）；治疗6、12个月 两组ALT 复常率无明显差异。治疗3、6、12 个月恩替卡韦组乙型肝炎病毒 （HBV ）-DNA 转阴率均明显高于阿德福韦酯 组，差异有统计学意义 （P ＜0.05）。治疗3、6、12个月恩替卡韦组乙型肝炎E 抗原 （HBeAg ）转阴率均明显高于阿德福韦 酯组，差异有统计学意义 （P ＜0.05）。治疗 12个月恩替卡韦组的ALT 复常率、HBV-DNA 转阴率、HBeAg 转阴率的C/E 分 别为273.3、352.6、911.0，阿德福韦酯组分别为 194.2 、328.6、908.6 。将阿德福韦酯组作为参照，恩替卡韦组HBV-DNA 转 阴率及HBeAg 转阴率的增量成本-效果 （△C/ △E ）分别为 129.7、182.1。结论 从短期看，阿德福韦酯治疗慢性乙型肝炎的 疗效尚可，药物经济学价值较高，而恩替卡韦虽然疗效更好，但疗效与成本尚未达到理想的平衡。 关键词：慢性乙型肝炎；恩替卡韦；阿德福韦酯；成本-效果分析 中图分类号：R956 文献标志码：A 文章编号：1674-6376 （2018 ）12-2322-04 DOI ：10.7501/j.issn.1674-6376.2018.12.039 Cost-effectiveness analysis of different drugs in patients with chronic hepatitis B ZHANG Yafeng, WANG Peng Weinan Central Hospital, Weinan 714000, China Abstract : Objective To analysis the cost-effectiveness analysis of different drugs in patients with chronic hepatitis B.Methods 84 patients with chronic hepatitis B were randomly divided into Entecavir (ETV) group with 40 cases and Adefovir dipivoxil (ADV) group with 44 cases, and pharmacoeconomic analysis of cost effectiveness (C/E) were conducted.Results ALT complex rate, HBV- DNA negative rate and HBeAg negative rate after 12 months treatment of the ETV group were 100.0%, 77.5% and 30.0%, and of the ADV group were 100.0%, 59.1% and 13.6%, the HBV-DNA negative rate and HBeAg negative rate between the two groups were statistical significant (P 0.05). The C/E of ALT complex rate, HBV-DNA negative rate and HBeAg negative rate of the ETV group were 273.3,352.6 and 911.0, and of the ADV group were 194.2 ,328.6 and 908.6.ADV group as a reference, the △C/ △E of HBV-DNA negative rate and HBeAg negative rate of